These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33748434)

  • 1. Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review.
    Belleudi V; Marchetti F; Finocchietti M; Davoli M; Addis A
    BMJ Paediatr Open; 2021; 5(1):e000985. PubMed ID: 33748434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.
    Belleudi V; Trotta F; Pinnarelli L; Davoli M; Addis A
    Arch Dis Child; 2018 Dec; 103(12):1163-1167. PubMed ID: 30217858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants.
    Duppenthaler A; Gorgievski-Hrisoho M; Aebi C
    Swiss Med Wkly; 2001 Mar; 131(11-12):146-51. PubMed ID: 11416887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
    Chida-Nagai A; Sato H; Sato I; Shiraishi M; Sasaki D; Izumi G; Yamazawa H; Cho K; Manabe A; Takeda A
    Eur J Pediatr; 2022 Feb; 181(2):539-547. PubMed ID: 34417646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK.
    Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J
    J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
    Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
    Paes B; Mitchell I; Li A; Lanctôt KL
    Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).
    Paes B; Mitchell I; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2703-11. PubMed ID: 22546928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
    Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
    J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
    Lewis L; Sinha I; Losty PD
    Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
    Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
    Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.